10/3/2006

The National Eye Institute may test Genentech's eye drug Lucentis and its cancer drug Avastin to compare the two in treating age-related macular degeneration. However, the institute said some major funding issues remain in creating the trial.

Full Story:
Bloomberg

Related Summaries